OdlindBHartvigPLindstromBLonnerholmGTufvesonGGrefbergN. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uraemic patients. Int J Immuno-pharmacol1986;8:1–11.
2.
DingTLGambertoglioJGAmendWJCBirnbaumJBenetLZ. Azathioprine bioavailability and pharmacokinetics in kidney transplant patients. Clin Pharmacol Ther1980;27:250.
3.
WeinshilboumRMSladekSL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet1980;32:651–62.
4.
GrantDMTangBKCampbellMEKalowW. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol1986;21:454–8.
5.
GuercioliniRSzumlanskiCWeinshilboumRM. Human liver xanthine oxidase: Nature and extent of individual variation. Clin Pharmacol Ther1991;50:663–72.
6.
SauerBHHantkeUWilmannsW. Azathioprine lympho-toxicity. Potentially lethal damage by its imidazole derivatives. Arzneim-Forsch/Drug Res1988;38:820–4.
7.
MaddocksJLLennardLAmessJAmosRThomasMeyrick R. Azathioprine and severe bone marrow depression. Lancet1986;i:156.
8.
LennardLVan LoonJAWeinshilboumRM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther1989;46:149–54.
9.
LennardLVan LoonJALilleymanJSWeinshilboumRM. Thiopurine pharmacogenetics in leukaemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther1987;41:18–25.
10.
LennardLLilleymanJSVan LoonJWeinshilboumRM. Childhood acute lymphoblastic leukaemia: Genetic variation in response to 6-mercaptopurine. Lancet1990;336:225–9.
LennardL. Assay of 6-thionosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatog1987;423:169–78.
13.
WeinshilboumRMRaymondFAPaziminoPA. Human erythrocyte thiopurine methyl transferase: Radiochemical microassay and biochemical properties. Clin Chim Acta1978;85:323–33.
14.
WitteASCornblathDRSchatzNJLisakRP. Monitoring azathioprine therapy in myasthenia gravis. Neurology1986;36:1533–4.
15.
LennardLMurphyMFMaddocksJL. Severe megaloblastic anaemia associated with abnormal azathioprine metabolism. Br J Clin Pharmacol1984;17:171–2.
16.
JeurissenMECBoerboomsAMThVan De PutteLBA. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis1988;47:503–5.
17.
KolleG. Knochenmarksschadigung bei immunsuppressiver therapie der juvenilen rheumatoiden arthritis und des Still-syndromes mit azathioprin. Dtsch Med Wochenschr1969;94:2268–73.
18.
LorenzenIBrunCVidebaekA. Treatment of immunological diseases with cytostatics. Acta Med Scand1969;185:501–6.
19.
GinzlerESharonEDiamondHKaplanD. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum1975;18:27–34.
20.
SingletonJWLawDHKelleyMLMekhjianHSSturdevantRAL. National cooperative Crohn's disease study: Adverse reactions to study drugs. Gastroenterology1979;77:870–82.
PresentDHKorelitzBIWischNGlassJLSacharDBPasternackBS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med1980;302:981–7.
23.
MertensHGHertelGReutherPRickerK. Effect of immunosuppressive drugs (Azathioprine). Ann NY Acad Sci1981;377:691–9.
24.
HaasJPatzoldU. Ueber die Blutbildveraenderungen bei langfristiger Behandlung der Multipen Sklerose und Myasthenie mit azathioprin. Nervenarzt1982;53:105–9.
25.
HallBMTillerDJHorvathJS. Treatment of renal transplantation rejection. Cyclosporin A versus conventional treatment with azathioprine, prednisolone and antithymocyte immunoglobulin in primary cadaveric renal transplantation. Med J Aust1985;142:179–85.
26.
KisselJTLevyRJMendellJRGriggsRC. Azathioprine toxicity in neuromuscular disease. Neurology1986;36:35–9.
27.
KvienTKHoyeraalHMSandstadB. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: A single centre double blind comparative study. J Rheumatol1986;13:118–23.
28.
HohlfeldRMichelsMHeiningerKBesingerUToykaKV. Azathioprine toxicity during long-term immunosuppression of generalised myasthenia gravis. Neurology1988;38:258–61.
29.
DenmanEJDenmanAMGreenwoodBMGallDHeathRB. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis1970;29:220–31.
30.
O'DonoghueDPDawsonAMPowell-TuckJBrownRLLennard-JonesJE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978;ii:955–7.
31.
TaguchiHYoshimotoSMachidaK. A case of megaloblastic anaemia induced by azathioprine. Rinsho Ketsocki (Japanese J Clin Haematol)1980;21:660–4.
32.
BaconBRTreuhaftWHGoodmanAM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch Intern Med1981;141:223–6.
33.
GoadsbyPJDayROKwanYLMinersJBirkettDJ. 6-mercaptopurine-related leucopenia and in vivo xanthine oxidase activity. Lancet1986;ii:869–70.
34.
VerhelstJAVan Den EndenEMathysR. Rapidly evolving azathioprine induced pancytopenia. J Rheumatol1987;14:862.
35.
NossentJCSwaakAJG. Pancytopenia in systemic lupus erythematosus related to azathioprine. J Intern Med1990;227:69–72.
36.
WhisnantJKPelkeyR. Rheumatoid arthritis: Treatment with azathioprine (IMURAN(R)). Clinical side-effects and laboratory abnormalities. Ann Rheum Dis1982;41(Suppl):44–66.
37.
LawsonDHLovattGEGurtonCSHenningsRC. Adverse effects of azathioprine. Adv Drug React Ac Pois Rev1984;3:161–71.
38.
DeckerJLSteinbergAD. Immunoregulatory drugs. In: McCarthyDJ, ed. Arthritis and allied conditions. Philadelphia: Lee & Febiger, 1985;529–30.
39.
LennardLHarringtonCIWoodMMaddocksJL. Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris. Br J Clin Pharmacol1987;23:229–33.
40.
APBI.Association of the British Pharmaceutical Industry Data Sheet Compendium. Datapharm Publications Ltd., 1990–1991:307–8, 317–18.